About us Contacts Drug interactions: 390 212
Drug search by name

Nerlynx and PCE Dispertab

Determining the interaction of Nerlynx and PCE Dispertab and the possibility of their joint administration.

Check result:
Nerlynx <> PCE Dispertab
Relevance: 13.07.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Erythromycin may significantly increase the blood levels of neratinib. This may increase side effects such as nausea, vomiting, diarrhea, abdominal pain, decreased appetite, mouth sores, and liver problems. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of neratinib, which is primarily metabolized by the isoenzyme. In a study with 24 healthy volunteers, administration of a single 240 mg oral dose of neratinib with the potent CYP450 3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased neratinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 3.2- and 4.8-fold, respectively, compared to administration of neratinib alone. Ketoconazole also reduced the mean apparent oral clearance of neratinib by 75% and increased its mean elimination half-life by approximately 6 hours. Simulations using physiologically-based pharmacokinetic (PBPK) models indicate that moderate CYP450 3A4 inhibitors may increase the Cmax and AUC of neratinib by 6% and 19%, respectively.

MANAGEMENT: Given the potential for increased risk of toxicity, concomitant use of neratinib with potent or moderate inhibitors of CYP450 3A4 should generally be avoided. According to some authorities, if the CYP450 3A4 inhibitor cannot be avoided, the dose of neratinib should be reduced to 40 mg once daily with a strong CYP450 3A4 inhibitor and 200 mg once daily with a moderate CYP450 3A4 inhibitor. The previous dose of neratinib may be resumed following discontinuation of a strong or moderate CYP450 3A4 inhibitor.

References
  • Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7
  • "Product Information. Nerlynx (neratinib)." Puma Biotechnology, Inc., Los Angeles, CA.
  • Cerner Multum, Inc. "Australian Product Information." O 0
Nerlynx

Generic Name: neratinib

Brand name: Nerlynx

Synonyms: n.a.

PCE Dispertab

Generic Name: erythromycin

Brand name: EES. Granules, EES-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, PCE Dispertab, E. E. S, EryPed, Erythrocin, Erythromycin Filmtabs, Erythromycin Lactobionate - IV

Synonyms: PCE Dispertab (Oral), PCE, PCE (Oral)

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction